TODD STRATEGY GROUP

Lobbying for BIOGEN, INC. · Biotechnology Company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Medicare/Medicaid

Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care.

Health Issues

Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.